State-of-the-art therapies for fragile X syndrome

Area of Science:

• Genetics
• Neuroscience
• Developmental Biology

Background:

• Fragile X syndrome (FXS) is a leading genetic cause of intellectual disability and autism spectrum disorder.
• It results from a full mutation (over 200 CGG repeats) in the FMR1 gene.
• Individuals with FXS often experience behavioral, sleep, anxiety, attention, learning, and speech challenges.

Purpose of the Study:

• To review current and emerging therapeutic strategies for Fragile X syndrome.
• To highlight the effectiveness of targeted treatments and the potential of gene therapy.

Main Methods:

• Review of current literature on Fragile X syndrome treatments.
• Analysis of existing non-pharmacological therapies and pharmacotherapies.
• Exploration of emerging gene therapy approaches.

Main Results:

• A combination of non-pharmacological therapies and pharmacotherapy is the most effective current treatment for FXS.
• Targeted treatments like metformin, sertraline, and cannabidiol are available for symptom management.
• Gene therapy is a rapidly developing prospective treatment option for FXS.

Conclusions:

• Targeted treatment represents the optimal current therapeutic strategy for Fragile X syndrome.
• Gene therapy shows significant potential as a future treatment for FXS, pending efficacy and safety demonstrations.